ANAB
AnaptysBio, Inc.
Biotechnology · Healthcare · United States
48.64
close · 2026-10-29
value
37
cheaper than peers37
quality
7
stronger fundamentals7
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| forward P/E | 10.72× | 82 |
| price to sales | 7.00× | 67 |
| cash flow yield, latest year | 1.1% | 59 |
| cash flow yield, 2 years ago | -7.0% | 50 |
| earnings yield, latest year | -0.8% | 41 |
| earnings yield, 2 years ago | -10.4% | 41 |
| earnings yield, 3 years ago | -7.8% | 41 |
| cash flow yield, 3 years ago | -4.3% | 41 |
| earnings yield, 1 year ago | -8.8% | 32 |
| cash flow yield, 1 year ago | -7.8% | 32 |
| EV to EBITDA | 38.64× | 28 |
| price to book | 136.63× | 1 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -135.5% | 51 |
| revenue growth | -8.0% | 29 |
| return on equity | -114.6% | 22 |
| debt to equity | 2175.8% | 1 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | $8.3M |
| employees | 104 |
| first trade | 2017-01-26 |
| next earnings | 2026-09-21 |
| fundamentals updated | 2026-09-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.46 | -5.12 | -6.08 | -4.57 |
| free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M |
| net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M |
| revenue | $234.6M | $91.3M | $17.2M | $10.3M |
| unusual items | $0 | $0 | -$7.3M | $0 |